[Use of erythropoietin in patients with chronic renal insufficiency and in hemodialysis].
Erythropoietin (EP) injected subcutaneously (SC) 2 or 3 times a week, respectively, or intravenously (IV) 3 times a week, increased the hemoglobin and the hematocrit of all the patients so treated. The total units of EP used was less when it was administered SC. EP once or twice a week, respectively, administered SC also increased the hemoglobin and hematocrit in each case, and the total amount of EP used was also less.
Cuero
C J
CJ
Servicio de Nefrología, Complejo Hospitalario Metropolitano.
Pérez Guardia
E
E
de Rivera
C
C
D000328:Adult; D000740:Anemia / Q000097:blood / Q000209:etiology / Q000628:therapy*; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D006400:Hematocrit; D006441:Hemoglobin A; D006801:Humans; D007275:Injections, Intravenous; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*
D004921:Erythropoietin; D006441:Hemoglobin A
Uso de eritropoyetina en pacientes con insuficiencia renal crónica y en hemodiálisis.